Business Wire

EEP-LEGAL

8.1.2021 17:03:29 CET | Business Wire | Press release

Share
EEP Legal Law Firm Announces: EU Corporate Coup: Covert Takeover Creates Dutch Monopoly of Leading Greek Corporations

Netherlands-owned Reggeborgh , has assumed control of 95% of Greek tolls by monopolising multiple Greek markets and defying EU competition regulations. Reggeborgh has acquired minority shares in Gek Terna Group and Ellaktor Group , Greece’s two leading business groups in the Construction, Renewable Energy, and Concessions (Handling, Maintenance and Operation of Toll Motorways). By controlling these companies, Reggeborgh stands to benefit from 32 billion euros of Covid-19 emergency relief funding which is being redirected into the country’s infrastructure, renewables, and construction.

In response, Ellaktor minority shareholder Mr. Michail Koulas has filed a complaint with the European Commission Directorate-General for Competition . According to the Complaint, dated 31.12.2020, Reggeborgh - parent company of Dutch Construction/Real Estate Market Leader VolkerWessels - follows a strategy of monopolization of Greek Construction, Renewable Energy Sources, and the Concession markets. Reggeborgh acquired the majority shares in Gek Terna (31% since March 2019) and Ellaktor (27% since December 2020). Considering low participation levels in both companies' General Assemblies REGGEBORGH now controls their decision making and management. Reggeborgh now has control of more than 95% of the Concessions market (Handling, Maintenance and Operation of Toll Motorways).

Mr. Koulas’s complaint details Reggeborgh's anti-competitive practice of abusing its market dominance to extinguish competition in breach of European Union competition law. Reggeborgh has illegally created a dominant and super-dominant position in segments and subsegments (Markets and Submarkets) crucial for consumer wellbeing and distorts competition in the Greek Geographical Market more widely.

According to Mr Koulas, his intent is:

“To ensure that the concentration at hand is duly examined by the competent competition authorities. Minority shareholders find themselves trapped in a Shareholder Pattern that has not been cleared by competent authorities. Competition and antitrust laws have to be enforced since they are designed to ensure that dominant companies – like the Dutch behemoth REGGEBORGH – are not allowed to foreclose competition illegally. We’re asking the EU to be a neutral party that will examine the facts and enforce the law.”

Ioannis Papanastasopoulos (Attorney at Law, Managing Partner of EEP Legal ) said:

"The case has been referred to the Competent Authorities i.e. Directorate General Competition and we expect its immediate action and scrutiny. The subject under examination is rather sensitive, since 32 billion euros of emergency/relief fund for Covid 19 for Greece will be channeled to Greek infrastructure renewables and construction markets.”

Emmanouil Margomenos (Attorney at Law) senior legal counsel for the team instructed to file the complaint said:

“There are obvious implications involved to the GEK TERNA / ELLAKTOR acquisition and concentration to a single undertaking. Those two market leaders becoming one entity under single control of REGGEBORGH results in REGGEBORGH controlling every single kilometre of toll motorway in Greece.”

The European Commission is already reviewing the complaint and will decide whether to open a formal investigation into Reggeborgh ’s anti-competitive practices.

Ioannis Papanastasopoulos,

EEP LEGAL, MANAGING PARTNER

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye